• Aesyntix Health (Roseville, California) said it has launched Aesyntix PaidRight, the first electronic remittance analyzer designed specifically to help dermatologists streamline reimbursement, improve operational efficiencies and accelerate cash flow. The solution is powered by RemitDATA (Memphis, Tennessee), a provider of web-based reimbursement tools and payer benchmarking. Aesyntix PaidRight helps dermatology practices improve reimbursement efficiencies, reduce denials and underpayments, and increase profitability by analyzing the electronic remittance advice. The web-based solution complements Aesyntix Health's revenue cycle management services provided to current dermatology medical billing customers and works alongside any practice management or billing system to improve reimbursement efficiencies and increase revenue.

• BioImagene (Cupertino, California) reported the launch of Virtuoso the company's new digital pathology solution. Virtuoso is a comprehensive suite of web-based software applications that work with BioImagene's iScan slide scanners to provide an end-to-end workflow solution. It is a Role-Based system and it enables the various stakeholders, or roles – Pathologist, Histo-technologist, Lab Administrator, Clinician, etc – to improve the efficiency and quality of the various steps in the Anatomical Pathology workflow. It allows the user to scan glass slides and then perform a wide range of functions - view, manage, manipulate, analyze, report and collaborate – in the digital form.

• Positron (Fishers, Indiana) reported the results from an independent study on radiation exposure of technologists administering FDG. Positron's Tech-Assist is a heavy duty syringe shield (PIG) mounted on a portable cart system. This system is designed to reduce or limit exposure, heavy lifting injuries and repetitive motion injuries that occur during Nuclear Medicine injection applications. The Tech-Assist was designed with the ALARA principles of time, distance and shielding in mind. The Tech-Assist uses tungsten for all shielding. The cart enables the user to transport the PIG to and from the injection room with ease and adjusts to various height levels allowing for the injection of ambulatory or supine patients.

• Provista Life Sciences (Phoenix) reported a limited national rollout of the BT Test, a new predictive blood test to aid healthcare providers in the early detection of breast cancer. Through a partnership with MedicExams, a national network of healthcare testing facilities, women can now take the BT Test in 27 states nationwide. The BT Test, or Biomarker Translation Test, finds multiple cancer-related proteins in the blood and combines the results with the patient's medical profile to help physicians in their efforts to find breast cancer as early as possible. Clinical research conducted on the BT Test showed an accuracy rate above 80%. MedicExams is a network of experienced medical professionals who conduct physical examinations, testing and personal health interviews, primarily for the life and health insurance industry.

• pSivida (Watertown, Massachusetts) reported the completion of enrollment of the BrachySil (P32 BioSilicon) dose-ranging clinical trial. This dose ranging study follows a safety study of BrachySil in patients with inoperable pancreatic cancer. This first study had shown BrachySil in combination with standard chemotherapy (gemcitabine) was well tolerated with no clinically significant adverse events related to the device. The data also showed disease control in 82% of patients and an overall median survival of people in the study of 309 days. BrachySil also was found to be easily deliverable by endoscopic ultrasound.

• SpectraScience (San Diego) said the FDA has given approval to manufacture its LUMA Cervical Cancer Imaging System in its San Diego facility. The LUMA Cervical Imaging System was developed to improve the detection of high-grade, pre-cancerous cervical abnormalities that have the potential to become invasive cancer. It is estimated that pre-cancerous cervical disease goes undiagnosed in about 200,000 American women each year. The LUMA System provides a safe, non-invasive and effective method, that when used as an adjunct to colposcopy, has been demonstrated to uncover at least 26% more high-grade precancerous disease than colposcopy alone.

• Xoft (Sunnyvale, California) said it has received FDA clearance for a skin and surface treatment applicator for use with the Axxent Electronic Brachytherapy (eBx) system to deliver surface brachytherapy, including Intraoperative Radiation Therapy. The Axxent System is designed to deliver non-radioactive therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue. Designed to deliver electronic, X-ray-based radiation treatment, the proprietary Axxent treatment platform can be used in many clinical settings. Treatment can be performed without the need for a shielded room, allowing the radiation oncologist and other medical personnel to be present during treatment delivery and minimizing patient anxiety.

• Zebra Technologies (Vernon Hills, Illinois) has introduced a new line of soft, easy-to-wear Z-Band Direct and Z-Band QuickClip wristbands for infants to ensure comfort and improve safety. Made of a soft nylon material, the premium direct thermal wristbands by Zebra Technologies feature an adjustable design to ensure an optimal fit for small infant wrists. The bands, which support both linear and two-dimensional bar codes, include a flat surface print area that supports higher first-time scan rates and minimizes any scanning issues that may result from the curvature of an infant's wrist. The wristbands are designed for use with Zebra's desktop printers, including the new HC100 direct thermal cartridge printer.

No Comments